These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1975361)

  • 1. Treatment of insomnia with ritanserin.
    Dahlitz M; Wells P; James R; Idzikowski C; Parkes JD
    Lancet; 1990 Aug; 336(8711):379. PubMed ID: 1975361
    [No Abstract]   [Full Text] [Related]  

  • 2. GP admits to falsifying clinical trial of insomnia drug.
    Dyer C
    BMJ; 2016 Apr; 353():i2441. PubMed ID: 27122294
    [No Abstract]   [Full Text] [Related]  

  • 3. Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?
    Janssen PA
    J R Soc Med; 1987 Jul; 80(7):409-13. PubMed ID: 3116237
    [No Abstract]   [Full Text] [Related]  

  • 4. Ritanserin (R 55667) an original thymosthenic.
    Hoppenbrowers ML; Gelders Y; Vanden Bussche G
    Boll Chim Farm; 1986 Dec; 125(12):136S-147S. PubMed ID: 3109453
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of ritanserin on sleep disturbances of dysthymic patients.
    Paiva T; Arriaga F; Wauquier A; Lara E; Largo R; Leitao JN
    Psychopharmacology (Berl); 1988; 96(3):395-9. PubMed ID: 3146774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin antagonism in panic disorder: an open trial with ritanserin.
    Griez E; Pols H; Lousberg H
    Acta Psychiatr Belg; 1988; 88(5-6):372-7. PubMed ID: 3152708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritanserin in schizophrenic patients.
    Vinar O; Molcan J; Náhunek K; Svestka J; Zapletálek M
    Act Nerv Super (Praha); 1989 Jun; 31(2):107-9. PubMed ID: 2508405
    [No Abstract]   [Full Text] [Related]  

  • 8. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam.
    Ceulemans DL; Hoppenbrouwers ML; Gelders YG; Reyntjens AJ
    Pharmacopsychiatry; 1985 Sep; 18(5):303-5. PubMed ID: 3931107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of repeated ritanserin on middle-aged poor sleepers.
    Adam K; Oswald I
    Psychopharmacology (Berl); 1989; 99(2):219-21. PubMed ID: 2508157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
    Bressa GM; Marini S; Gregori S
    Int J Clin Pharmacol Res; 1987; 7(2):111-9. PubMed ID: 3108171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.
    Monti JM
    Drugs Today (Barc); 2010 Mar; 46(3):183-93. PubMed ID: 20467592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study to establish the indication for the selective S2 antagonist ritanserin.
    Klieser E; Strauss WH
    Pharmacopsychiatry; 1988 Nov; 21(6):391-3. PubMed ID: 3149751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin.
    Miller CH; Fleischhacker WW; Ehrmann H; Kane JM
    Psychopharmacol Bull; 1990; 26(3):373-6. PubMed ID: 1980375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin.
    Torr S; Noble MI; Folts JD
    Cardiovasc Res; 1990 Jun; 24(6):465-70. PubMed ID: 2117499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymosthenic agents, a novel approach in the treatment of schizophrenia.
    Gelders YG
    Br J Psychiatry Suppl; 1989 Jul; (5):33-6. PubMed ID: 2481482
    [No Abstract]   [Full Text] [Related]  

  • 17. The relevance of pharmacological studies to sleep research in psychiatry.
    Janssen PA
    Pharmacopsychiatry; 1988 Jan; 21(1):33-7. PubMed ID: 3129746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological management of treatment-induced insomnia in ADHD.
    Kratochvil CJ; Lake M; Pliszka SR; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):499-501. PubMed ID: 15843773
    [No Abstract]   [Full Text] [Related]  

  • 19. 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.
    Fish LR; Gilligan MT; Humphries AC; Ivarsson M; Ladduwahetty T; Merchant KJ; O'Connor D; Patel S; Philipps E; Vargas HM; Hutson PH; MacLeod AM
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3665-9. PubMed ID: 15993598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).
    Martin P; Waters N; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1997; 104(4-5):561-4. PubMed ID: 9295186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.